Top-News
Pharmazeutika USA

Biogen News

Aktie
WKN:  789617 ISIN:  US09062X1037 US-Symbol:  BIIB
203,35 €
-2,30 €
-1,12%
22:56:44 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
145,30 Mio.
Marktkapitalisierung *
29,87 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq 100
IR-Website
zur Website
*Stand: 22.07.2023
Weiter abwärts? Short handeln - Jetzt mit Hebel 7,20: VD0CD6

Unternehmensmeldungen

25.04.24 - LYNX Analysen
Biogen: Unternehmen liefert Ergebnisse und die Aktie explodiert – jetzt kaufen?
Der bekannte Biotech-​Konzern hat gestern vor Börsenbeginn seine Ergebnisse zum abgelaufenen Quartal präsentiert. Die gute Nachricht vorweg. Das Unternehmen konnte die ...  Mehr »
25.04.24 - GlobeNewswire
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-​clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA ® CAMBRIDGE, Mass., ...
06.03.24 - GlobeNewswire
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA ...
04.03.24 - GlobeNewswire
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
New data advances understanding of new approaches to treating Alzheimer’s disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., ...
23.02.24 - GlobeNewswire
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
SOD1 -ALS is a devastating, uniformly fatal, and ultra-​rare genetic form of ALS affecting less than 1,000 people in Europe 1 With QALSODY, Biogen has advanced the role of ...
12.02.24 - GlobeNewswire
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Friedreich’s ataxia is a rare, genetic, life-​shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen ...
31.01.24 - GlobeNewswire
Biogen to Realign Resources for Alzheimer's Disease Franchise
Company to reprioritize resources allocated to ADUHELM ® (aducanumab-​avwa) to advance LEQEMBI ® (lecanemab-​irmb) and to develop new treatment modalities Biogen ...
19.12.23 - GlobeNewswire
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing ...
15.12.23 - GlobeNewswire
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Friedreich’s ataxia is a genetic, debilitating and life-​shortening neuromuscular disease 1 Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing ...
14.12.23 - GlobeNewswire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
ZURZUVAE, the first and only oral, once-​daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for ...
06.11.23 - GlobeNewswire
Biogen Appoints Monish Patolawala to its Board of Directors
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation
25.10.23 - GlobeNewswire
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No ...
25.10.23 - GlobeNewswire
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau targeting drug that shows ...
19.10.23 - GlobeNewswire
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
Late-​breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-​stage Alzheimer’s disease Additional late-​breaking presentations from the ...
29.09.23 - GlobeNewswire
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-​clinical and clinical data ...
26.09.23 - GlobeNewswire
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the ...
25.09.23 - GlobeNewswire
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate ...
06.09.23 - GlobeNewswire
Biogen Appoints Jane Grogan as Head of Research
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of ...
05.08.23 - GlobeNewswire
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at ...
28.07.23 - GlobeNewswire
Biogen to Acquire Reata Pharmaceuticals
SKYCLARYS ® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia   Proposed acquisition represents meaningful step forward in Biogen’s ...
20.07.23 - GlobeNewswire
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-​beta and tau, two underlying pathological hallmarks of Alzheimer’s disease

Newssuche

Videos

newspaper
13:20 Uhr +43,15%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »